» Articles » PMID: 25667224

Yet Another Function of P53--the Switch That Determines Whether Radiation-induced Autophagy Will Be Cytoprotective or Nonprotective: Implications for Autophagy Inhibition As a Therapeutic Strategy

Overview
Journal Mol Pharmacol
Date 2015 Feb 11
PMID 25667224
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

The influence of autophagy inhibition on radiation sensitivity was studied in human breast, head and neck, and non-small cell lung cancer cell lines, in cell lines that were either wild type or mutant/null in p53, and in cells where p53 was inducible or silenced. Whereas ionizing radiation promoted autophagy in all tumor cell lines studied, pharmacological inhibition of autophagy and/or genetic silencing of autophagy genes failed to influence sensitivity to radiation in p53 mutant Hs578t breast tumor cells, HN6 head and neck tumor cells, and H358 non-small cell lung cancer cells. The requirement for functional p53 in the promotion of cytoprotective autophagy by radiation was confirmed by the observation that radiation-induced autophagy was nonprotective in p53 null H1299 cells but was converted to the cytoprotective form with induction of p53. Conversely, whereas p53 wild-type HN30 head and neck cancer cells did show sensitization to radiation upon autophagy inhibition, HN30 cells in which p53 was knocked down using small hairpin RNA failed to be sensitized by pharmacological autophagy inhibition. Taken together, these findings indicate that radiation-induced autophagy can be either cytoprotective or nonprotective, a functional difference related to the presence or absence of function p53. Alternatively, these findings could be interpreted to suggest that whereas radiation can induce autophagy independent of p53 status, inhibition of autophagy promotes enhanced radiation sensitivity through a mechanism that requires functional p53. These observations are likely to have direct implications with respect to clinical efforts to modulate the response of malignancies to radiation through autophagy inhibition.

Citing Articles

The role of autophagy in hypoxia-induced radioresistance.

Hill R, Fok M, Grundy G, Parsons J, Rocha S Radiother Oncol. 2023; 189:109951.

PMID: 37838322 PMC: 11046710. DOI: 10.1016/j.radonc.2023.109951.


The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer.

Finnegan R, Elshazly A, Patel N, Tyutyunyk-Massey L, Tran T, Kumarasamy V Front Oncol. 2023; 12:966441.

PMID: 36741704 PMC: 9890056. DOI: 10.3389/fonc.2022.966441.


Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?.

Zaryouh H, Van Loenhout J, Peeters M, Vermorken J, Lardon F, Wouters A Cancers (Basel). 2022; 14(24).

PMID: 36551613 PMC: 9776372. DOI: 10.3390/cancers14246128.


-(4-fluorobenzyl) Arteannuin B induced interaction of ATF-4 and C/EBPβ mediates the transition of breast cancer cells from autophagy to senescence.

Bashir Mir K, Faheem M, Ahmad S, Rasool J, Amin T, Chakraborty S Front Oncol. 2022; 12:1013500.

PMID: 36465376 PMC: 9713483. DOI: 10.3389/fonc.2022.1013500.


Of the many cellular responses activated by TP53, which ones are critical for tumour suppression?.

Thomas A, Kelly G, Strasser A Cell Death Differ. 2022; 29(5):961-971.

PMID: 35396345 PMC: 9090748. DOI: 10.1038/s41418-022-00996-z.


References
1.
He C, Klionsky D . Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009; 43:67-93. PMC: 2831538. DOI: 10.1146/annurev-genet-102808-114910. View

2.
Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E . A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res. 2001; 61(2):439-44. View

3.
Carew J, Medina E, Esquivel 2nd J, Mahalingam D, Swords R, Kelly K . Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med. 2009; 14(10):2448-59. PMC: 2891399. DOI: 10.1111/j.1582-4934.2009.00832.x. View

4.
Liang X, de Vera M, Buchser W, Romo de Vivar Chavez A, Loughran P, Stolz D . Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res. 2012; 72(11):2791-801. PMC: 3417121. DOI: 10.1158/0008-5472.CAN-12-0320. View

5.
Bristol M, Emery S, Maycotte P, Thorburn A, Chakradeo S, Gewirtz D . Autophagy inhibition for chemosensitization and radiosensitization in cancer: do the preclinical data support this therapeutic strategy?. J Pharmacol Exp Ther. 2013; 344(3):544-52. PMC: 3583507. DOI: 10.1124/jpet.112.199802. View